Kineta rises on positive data from early-stage cancer trial
Brief: Kineta Announces Positive Kva12123 Monotherapy Safety And Biomarker Data From Its Ongoing Phase 1/2 Vista-101 Clinical Trial
Brief: Kineta Inc Regains Compliance With Alternative Standard Under Nasdaq Listing Rule 5550(B)(1)
Kineta Inc expected to post a loss of 62 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
Kineta to get $5 mln milestone payment from Merck, shares rise
Brief: Kineta To Receive $5 Mln Milestone Payment From Merck
Brief: Kineta Says Board Increased Size From Five To Seven Members On June 27
Brief: Kineta Inc - Co, Gigagen Entered Second Amendment To Option And License Agreement Under Vista Agreement
Kineta rises on narrower Q1 loss
Kineta Inc reports results for the quarter ended in March - Earnings Summary
Brief: Kineta Reports First Quarter 2023 Financial Results And Provides Corporate Update
Kineta Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: Kineta Inc And Investors Entered Into Amendment No. 4 To Securities Purchase Agreement
Brief: Kineta Inc. Announces Closing Of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Kineta Announces $6 Mln Registered Direct Offering
Brief: Kineta Unveils New Vista Biomarker Data And Kva12123 Phase 1/2 Clinical Trial Update At Aacr Annual Meeting 2023
Brief: Kineta Phase 1 Initial Data Readout Expected By End Of 2023
Brief: Kineta Appoints Internationally-Renowned Clinical Immuno-Oncology Experts To Its Scientific Advisory Board